Oligonucleotide Therapy Market: By Type (Antisense, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory, RNAi), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Others), By End User (Hospitals, Research Institutes, Others) and Geography 

Oligonucleotide Therapy Market size was valued at USD 5,183.6 million in 2023 and is expected to grow at an 18.2% CAGR from 2024 to 2030. Oligonucleotides are short-chain DNA or RNA which are generally made using automated synthesizers and the purification process is done by anion exchange chromatography and followed by the techniques of freezing and desalting. Moreover, the oligonucleotides can hold back the expression of specific genes which results in the development of brand-new oligonucleotides targeting certain genes and treating chronic diseases.

The increasing prevalence of infectious diseases such as chickenpox, diphtheria, and the common cold is expected to drive the growth of the oligonucleotides market over the forecast period. In addition, the development of more stable and prolonged half-life molecules due to the advancement of technologies and the upgradation of chemically synthesized oligonucleotides which is anticipated to boost the growth of the oligonucleotides market at a significant rate over the forecast period. Furthermore, an increasing number of mergers, acquisitions, and product launches among the manufacturers and market players to provide medical care to patients are expected to result in the expansion of the oligonucleotide therapy market over the forecast period. For instance, in February 2022, researchers at the University of Illinois Urbana developed a new miRNA point-of-care test for the detection of cancer. The test uses nanoparticles to capture tumor-specific microRNAs (miRNAs) in human serum.

However, the incapability to detect minor antibodies along with the strict regulations are expected to hold back the growth of the oligonucleotide therapy market over the forecast period. Moreover, an increasing number of innovative and technologically advanced product launches are anticipated to provide opportunities in the growth of the oligonucleotides market over the forecast period. Geographically, North America region held the major market share in 2022 and is expected to dominate the global oligonucleotide therapy market in the forecasted years.

Oligonucleotide Therapy Market Key Developments:

• In December 2022, GSK announced their collaboration with Wave Life Sciences to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets.